1-Methyltryptophan

1-Methyltryptophan

Names
Preferred IUPAC name 2-Amino-3-(1-methyl-1H-indol-3-yl)propanoic acid
Other names 1-Methyl-DL-tryptophan; DL-1-Methyltryptophan; ARBRIN; Indoximod
Identifiers
CAS Number	26988-72-7 (D/L) N 21339-55-9 (L) Y
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL504816  N ChEMBL514172  Y
ChemSpider	88584  Y
ECHA InfoCard	100.043.765
IUPHAR/BPS	4694
PubChem CID	98112
CompTox Dashboard (EPA)	DTXSID601314131
InChI InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16) Y Key: ZADWXFSZEAPBJS-UHFFFAOYSA-N Y InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16) Key: ZADWXFSZEAPBJS-UHFFFAOYSA-N
SMILES O=C(O)C(N)Cc2c1ccccc1n(c2)C
Properties
Chemical formula	C12H14N2O2
Molar mass	218.256 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N  verify  (what is  YN ?) Infobox references

1-Methyltryptophan is a chemical compound that is an inhibitor of the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO or INDO EC 1.13.11.52). ^[1] It is a chiral compound that can exist as both D- and L-enantiomers.

The L-isomer (L-1MT) inhibits IDO weakly but also serves as an enzyme substrate.

The D-isomer (D-1MT) does not inhibit IDO at all, but it can inhibit the IDO-related enzyme IDO2 ^[2] and restore mTOR signaling in cells starved of tryptophan due to IDO activity. ^[3] D-1MT is also known as indoximod and it was in clinical trials for cancer treatment, such as for advanced melanoma, in 2017. ^{[4] [ needs update ]}

A U.S. patent covering salt and prodrug formulations of indoximod was issued to NewLink Genetics on August 15, 2017 providing exclusivity until at least 2036. ^{[5] [6]}

References

1. Cady, SG; Sono, M (1991). "1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-3-benzo[b]thienyl-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase". Archives of Biochemistry and Biophysics. 291 (2): 326–33. doi:10.1016/0003-9861(91)90142-6. PMID   1952947.
2. Metz, R; Duhadaway, J. B.; Kamasani, U; Laury-Kleintop, L; Muller, A. J.; Prendergast, G. C. (2007). "Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan". Cancer Research. 67 (15): 7082–7. doi: 10.1158/0008-5472.CAN-07-1872 . PMID   17671174.
3. Metz, R; Rust, S; Duhadaway, J. B.; Mautino, M. R.; Munn, D. H.; Vahanian, N. N.; Link, C. J.; Prendergast, G. C. (2012). "IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan". OncoImmunology. 1 (9): 1460–1468. doi:10.4161/onci.21716. PMC   3525601 . PMID   23264892.
4. IDO Inhibitors Emerging as New Players on Checkpoint Blockade Scene. Aug 2017
5. "NewLink Genetics". finpedia.co. Retrieved 2019-05-09.
6. "NewLink Genetics Annual Report (Form 10-K)". fintel.io. April 9, 2018.